Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 10;70(8):1606-1612.
doi: 10.1093/cid/ciz431.

Evaluation of Intussusception After Oral Monovalent Rotavirus Vaccination in South Africa

Michelle J Groome  1   2 , Jacqueline E Tate  3 , Marion Arnold  4   5 , Milind Chitnis  6 , Sharon Cox  4 , Corné de Vos  5 , Mari Kirsten  7 , Susanna M le Grange  8 , Jerome Loveland  9 , Sello Machaea  6 , Ashwini Maharaj  10 , Nick Andrews  11 , Shabir A Madhi  1   2 , Umesh D Parashar  3
Affiliations

Evaluation of Intussusception After Oral Monovalent Rotavirus Vaccination in South Africa

Michelle J Groome et al. Clin Infect Dis. .

Abstract

Background: Postlicensure studies have shown an association between rotavirus vaccination and intussusception. We assessed the risk of intussusception associated with Rotarix (RV1) administration, at 6 and 14 weeks of age, in an upper-middle-income country, South Africa.

Methods: Active prospective surveillance for intussusception was conducted in 8 hospitals from September 2013 through December 2017. Retrospective case enrollment was done at 1 hospital from July 2012 through August 2013. Demographic characteristics, symptom onset, and rotavirus vaccine status were ascertained. Using the self-controlled case-series method, we estimated age-adjusted incidence rate ratios within 1-7, 8-21, and 1-21 days of rotavirus vaccination in children aged 28-275 days at onset of symptoms. In addition, age-matched controls were enrolled for a subset of cases (n = 169), and a secondary analysis was performed.

Results: Three hundred forty-six cases were included in the case-series analysis. Post-dose 1, there were zero intussusception cases within 1-7 days, and 5 cases within 8-21 days of vaccination. Post-dose 2, 15 cases occurred within 1-7 days, and 18 cases within 8-21 days of vaccination. There was no increased risk of intussusception 1-7 days after dose 1 (no cases observed) or dose 2 (relative incidence [RI], 1.71 [95% confidence interval {CI} .83-3.01]). Similarly, there was no increased risk 8-21 days after the first (RI, 4.01 [95% CI, .87-10.56]) or second dose (RI, .96 [95% CI, .52-1.60]). Results were similar for the case-control analysis.

Conclusions: The risk of intussusception in the 21 days after the first or second dose of RV1 was not higher than the background risk among South Africa infants.

Clinical trials registration: South African National Clinical Trial Register (DOH-27-0913-4183).

Keywords: infant; intussusception; rotavirus vaccine; safety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Age at rotavirus (Rotarix [RV1]) vaccination and at onset of intussusception symptoms among cases.
Figure 2.
Figure 2.
Cases of intussusception occurring during the first 60 days after dose 1 (A) and dose 2 (B) of rotavirus vaccine (Rotarix [RV1]). Three hundred thirteen intussusception cases occurred >60 days after dose 1; 183 cases occurred >60 days after dose 2.
See this image and copyright information in PMC

References

    1. Jiang J, Jiang B, Parashar U, Nguyen T, Bines J, Patel MM. Childhood intussusception: a literature review. PLoS One 2013; 8:e68482. - PMC - PubMed
    1. Mpabalwani EM, Mwenda JM, Tate JE, Parashar UD. Review of naturally occurring intussusception in young children in the WHO African region prior to the era of rotavirus vaccine utilization in the expanded programme of immunization. J Trop Pediatr 2017; 63:221–8. - PubMed
    1. Murphy TV, Gargiullo PM, Massoudi MS, et al. . Rotavirus Intussusception Investigation Team Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564–72. - PubMed
    1. Vesikari T, Matson DO, Dennehy P, et al. . Rotavirus Efficacy and Safety Trial (REST) Study Team Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23–33. - PubMed
    1. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. . Human Rotavirus Vaccine Study Group Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11–22. - PubMed

Publication types